Versor Investments LP Makes New $44,000 Investment in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Versor Investments LP acquired a new position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) during the third quarter, Holdings Channel.com reports. The firm acquired 26,400 shares of the biopharmaceutical company’s stock, valued at approximately $44,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Capital Advisors Wealth Management LLC increased its position in shares of Esperion Therapeutics by 22.9% in the 2nd quarter. Capital Advisors Wealth Management LLC now owns 26,800 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 5,000 shares during the last quarter. Boomfish Wealth Group LLC increased its position in shares of Esperion Therapeutics by 17.1% in the 3rd quarter. Boomfish Wealth Group LLC now owns 34,997 shares of the biopharmaceutical company’s stock worth $58,000 after purchasing an additional 5,102 shares during the last quarter. Summit Financial LLC increased its position in shares of Esperion Therapeutics by 26.4% in the 2nd quarter. Summit Financial LLC now owns 32,687 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 6,823 shares during the last quarter. National Bank of Canada FI increased its position in shares of Esperion Therapeutics by 115.9% in the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 10,225 shares during the last quarter. Finally, SG Americas Securities LLC increased its position in shares of Esperion Therapeutics by 45.3% in the 2nd quarter. SG Americas Securities LLC now owns 37,414 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 11,658 shares during the last quarter. Institutional investors and hedge funds own 47.39% of the company’s stock.

Esperion Therapeutics Stock Up 1.0 %

Shares of NASDAQ:ESPR opened at $2.12 on Monday. Esperion Therapeutics, Inc. has a fifty-two week low of $1.04 and a fifty-two week high of $3.40. The firm has a 50-day simple moving average of $1.97 and a 200 day simple moving average of $2.14. The company has a market cap of $417.71 million, a PE ratio of -3.31 and a beta of 0.96.

Analysts Set New Price Targets

ESPR has been the subject of several research analyst reports. Needham & Company LLC dropped their target price on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a research report on Friday, November 8th. Finally, StockNews.com downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $8.17.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.